MY05 selectively targets c-MYC in cells and disrupts MYC-MAX interaction. MY05 engages intracellular c-MYC, modulates c-MYC thermal stability, reduces c-MYC transcriptional targets, and possesses anticancer activity (TNBC, Triple-Negative Breast Cancer ) [1].
In Vivo, MY05 (10 mg/kg) inhibits MYC-driven solid tumor growth in TNBC mouse model[1].
In Vitro, MY05 exhibits IC50 values of 10.6 μM, 13.5 μM and 39.4 μM in MDA-MB 231, MDA-MB 468 and MCF-7 cells, respectively[1]. MY05 promotes apoptosis and inhibits MYC-Driven mammosphere growth[1].
References:
[1]. Oluwatosin A Obisesan, et al. Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC-MAX Heterodimerization. J Med Chem. 2025 Mar 27;68(6):6233-6251.
In Vivo, MY05 (10 mg/kg) inhibits MYC-driven solid tumor growth in TNBC mouse model[1].
In Vitro, MY05 exhibits IC50 values of 10.6 μM, 13.5 μM and 39.4 μM in MDA-MB 231, MDA-MB 468 and MCF-7 cells, respectively[1]. MY05 promotes apoptosis and inhibits MYC-Driven mammosphere growth[1].
References:
[1]. Oluwatosin A Obisesan, et al. Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC-MAX Heterodimerization. J Med Chem. 2025 Mar 27;68(6):6233-6251.